The SUCCESSA trial showed that hyaluronan-mediated motility receptor (HMMR) gene single nucleotide polymorphisms (SNPs) are significant predictors of CIN in female patients with breast cancer who underwent FEC chemotherapy13. The gene discussed is HMMR; the disease is breast carcinoma.